Cargando…

Serological investigation of SARS-CoV-2 infection in patients with suspect measles, 2017–2022

BACKGROUND: Several studies suggested that SARS-CoV-2 was already spreading worldwide during the last months of 2019 before the first outbreak was detected in Wuhan, China. Lombardy (Northern Italy) was the first European region with sustained SARS-CoV-2 transmission and recent investigations detect...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianchi, Silvia, Fappani, Clara, Gori, Maria, Canuti, Marta, Colzani, Daniela, Monti, Maria Cristina, Torriani, Camilla, Raviglione, Mario C., Zuccotti, Gianvincenzo, Tanzi, Elisabetta, Amendola, Antonella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357797/
https://www.ncbi.nlm.nih.gov/pubmed/37474969
http://dx.doi.org/10.1186/s12985-023-02117-9
_version_ 1785075572281442304
author Bianchi, Silvia
Fappani, Clara
Gori, Maria
Canuti, Marta
Colzani, Daniela
Monti, Maria Cristina
Torriani, Camilla
Raviglione, Mario C.
Zuccotti, Gianvincenzo
Tanzi, Elisabetta
Amendola, Antonella
author_facet Bianchi, Silvia
Fappani, Clara
Gori, Maria
Canuti, Marta
Colzani, Daniela
Monti, Maria Cristina
Torriani, Camilla
Raviglione, Mario C.
Zuccotti, Gianvincenzo
Tanzi, Elisabetta
Amendola, Antonella
author_sort Bianchi, Silvia
collection PubMed
description BACKGROUND: Several studies suggested that SARS-CoV-2 was already spreading worldwide during the last months of 2019 before the first outbreak was detected in Wuhan, China. Lombardy (Northern Italy) was the first European region with sustained SARS-CoV-2 transmission and recent investigations detected SARS-CoV-2-RNA-positive patients in Lombardy since late 2019. METHODS: We tested for anti-SARS-CoV-2 IgG all serum samples available in our laboratory (N = 235, collected between March 2017 and March 2022) that we received within the framework of measles/rubella surveillance from measles and rubella virus-negative patients. RESULTS: Thirteen of 235 samples (5.5%) were IgG-positive. The positivity rate increased starting in 2019 and was significantly different from the expected false positive rate from 2019 onwards. Additionally, in 2019 the percentage of IgG-positive patients was significantly lower among SARS-CoV-2 RNA-negative patients (3/92) compared to SARS-CoV-2 RNA-positive patients (2/7, p = 0.04). The highest percentage of IgG positivity in the pre-pandemic period was recorded during the second half of 2019. This coincided with an increase in negativity for measles and a widening of the peak of the number of measles discarded cases per 100,000 inhabitants, indicating a higher-than-normal number of measles-negative patients experiencing fever and rash. This also coincided with the first patient positive for SARS-CoV-2 RNA (September 12th, 2019); this patient was also positive for anti-SARS-CoV-2 IgG and IgM. CONCLUSIONS: Although the number of samples was low and one cannot conclusively establish that the virus started circulating in Lombardy around September 2019, our findings should stimulate similar research investigating the possibility of undetected SARS-CoV-2 pre-pandemic circulation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-02117-9.
format Online
Article
Text
id pubmed-10357797
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103577972023-07-21 Serological investigation of SARS-CoV-2 infection in patients with suspect measles, 2017–2022 Bianchi, Silvia Fappani, Clara Gori, Maria Canuti, Marta Colzani, Daniela Monti, Maria Cristina Torriani, Camilla Raviglione, Mario C. Zuccotti, Gianvincenzo Tanzi, Elisabetta Amendola, Antonella Virol J Brief Report BACKGROUND: Several studies suggested that SARS-CoV-2 was already spreading worldwide during the last months of 2019 before the first outbreak was detected in Wuhan, China. Lombardy (Northern Italy) was the first European region with sustained SARS-CoV-2 transmission and recent investigations detected SARS-CoV-2-RNA-positive patients in Lombardy since late 2019. METHODS: We tested for anti-SARS-CoV-2 IgG all serum samples available in our laboratory (N = 235, collected between March 2017 and March 2022) that we received within the framework of measles/rubella surveillance from measles and rubella virus-negative patients. RESULTS: Thirteen of 235 samples (5.5%) were IgG-positive. The positivity rate increased starting in 2019 and was significantly different from the expected false positive rate from 2019 onwards. Additionally, in 2019 the percentage of IgG-positive patients was significantly lower among SARS-CoV-2 RNA-negative patients (3/92) compared to SARS-CoV-2 RNA-positive patients (2/7, p = 0.04). The highest percentage of IgG positivity in the pre-pandemic period was recorded during the second half of 2019. This coincided with an increase in negativity for measles and a widening of the peak of the number of measles discarded cases per 100,000 inhabitants, indicating a higher-than-normal number of measles-negative patients experiencing fever and rash. This also coincided with the first patient positive for SARS-CoV-2 RNA (September 12th, 2019); this patient was also positive for anti-SARS-CoV-2 IgG and IgM. CONCLUSIONS: Although the number of samples was low and one cannot conclusively establish that the virus started circulating in Lombardy around September 2019, our findings should stimulate similar research investigating the possibility of undetected SARS-CoV-2 pre-pandemic circulation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12985-023-02117-9. BioMed Central 2023-07-20 /pmc/articles/PMC10357797/ /pubmed/37474969 http://dx.doi.org/10.1186/s12985-023-02117-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Brief Report
Bianchi, Silvia
Fappani, Clara
Gori, Maria
Canuti, Marta
Colzani, Daniela
Monti, Maria Cristina
Torriani, Camilla
Raviglione, Mario C.
Zuccotti, Gianvincenzo
Tanzi, Elisabetta
Amendola, Antonella
Serological investigation of SARS-CoV-2 infection in patients with suspect measles, 2017–2022
title Serological investigation of SARS-CoV-2 infection in patients with suspect measles, 2017–2022
title_full Serological investigation of SARS-CoV-2 infection in patients with suspect measles, 2017–2022
title_fullStr Serological investigation of SARS-CoV-2 infection in patients with suspect measles, 2017–2022
title_full_unstemmed Serological investigation of SARS-CoV-2 infection in patients with suspect measles, 2017–2022
title_short Serological investigation of SARS-CoV-2 infection in patients with suspect measles, 2017–2022
title_sort serological investigation of sars-cov-2 infection in patients with suspect measles, 2017–2022
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357797/
https://www.ncbi.nlm.nih.gov/pubmed/37474969
http://dx.doi.org/10.1186/s12985-023-02117-9
work_keys_str_mv AT bianchisilvia serologicalinvestigationofsarscov2infectioninpatientswithsuspectmeasles20172022
AT fappaniclara serologicalinvestigationofsarscov2infectioninpatientswithsuspectmeasles20172022
AT gorimaria serologicalinvestigationofsarscov2infectioninpatientswithsuspectmeasles20172022
AT canutimarta serologicalinvestigationofsarscov2infectioninpatientswithsuspectmeasles20172022
AT colzanidaniela serologicalinvestigationofsarscov2infectioninpatientswithsuspectmeasles20172022
AT montimariacristina serologicalinvestigationofsarscov2infectioninpatientswithsuspectmeasles20172022
AT torrianicamilla serologicalinvestigationofsarscov2infectioninpatientswithsuspectmeasles20172022
AT raviglionemarioc serologicalinvestigationofsarscov2infectioninpatientswithsuspectmeasles20172022
AT zuccottigianvincenzo serologicalinvestigationofsarscov2infectioninpatientswithsuspectmeasles20172022
AT tanzielisabetta serologicalinvestigationofsarscov2infectioninpatientswithsuspectmeasles20172022
AT amendolaantonella serologicalinvestigationofsarscov2infectioninpatientswithsuspectmeasles20172022